| Code | CSB-RA004936MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to ABBV-927, designed for research targeting CD40, a member of the tumor necrosis factor receptor superfamily. CD40 is a costimulatory protein expressed on antigen-presenting cells, B cells, and various non-immune cells, playing a crucial role in adaptive immunity through its interaction with CD40 ligand (CD40L). This interaction regulates B cell activation, immunoglobulin class switching, and the generation of memory B cells. CD40 signaling is implicated in autoimmune diseases, inflammatory conditions, and cancer, where it influences both tumor immunity and tumor cell survival depending on the cellular context.
ABBV-927 is an investigational agonistic antibody that has been evaluated in clinical studies for its potential to enhance anti-tumor immune responses in cancer therapy. This biosimilar provides researchers with a valuable tool for investigating CD40-mediated immune mechanisms, studying tumor immunology, evaluating therapeutic strategies in oncology models, and exploring the role of costimulatory pathways in immune regulation and disease pathogenesis.
There are currently no reviews for this product.